Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721615 | 0.93 | PTGS2 (0.47) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6726512 | 0.92 | PTGS2 (0.49) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6719228 | 0.92 | PTGS2 (0.49) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6719265 | 0.92 | PTGS2 (0.49) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6723452 | 0.91 | PTGS2 (0.48) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6730160 | 0.91 | PTGS2 (0.45) | PTGS2PTGS1BRD4 | |
| SCHEMBL6723064 | 0.91 | PTGS2 (0.50) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6721852 | 0.90 | PTGS2 (0.47) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6733563 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6730008 | 0.88 | PTGS2 (0.44) | PTGS2PTGS1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885CA1 1851/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885CA1 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.